• Journal of Hospice and Palliative Care
• /
• 제8권1호
• /
• pp.1-7
• /
• 2005

목적: 본 연구는 입원한 폐암환자의 수면의 질을 파악하기 위한 것으로 그 구체적인 목적은 대상자의 제(인구사회학적, 질병관련) 특성을 파악하고, 수면의 질과 제 특성에 따른 수면의 질을 파악하는 것이다. 방법: 연구대상은 B시에 소재한 K대학 부속병원에서 임의표집 한 입원 폐암환자 50명을 대상으로 하였다. 자료수집기간은 2001년 1월 21일부터 4월8일까지였다. 자료수집방법은 환자에게 설문지를 배부하여 대상자가 직접 기입하도록 하여 회수하였다. 측정도구는 수면의 질을 측정하기 위해 오진주 등(1999)이 개발한 15문항으로 구성된 '수면측정도구 A'를 사용하였다. 자료분석은 SPSS 10.0 프로그램을 이용하여 통계처리 하였으며, 실수와 백분율, 평균, 평균평점과 표준편차, t-test, ANOVA, Post-hoc test(Scheffe's test)로 분석하였다. 결과: 본 연구의 결과는 다음과 같았다. 1. 대상자의 수면의 질은 평균 $35.64{\pm}7.59$로 나타났다. 2. 대상자의 제 특성과 관련된 수면의 질은 현재 통증(t=-1.943, P=.046), 주간호제공자(F=2.863, P=.047), 체중의 변화(F=5.906, P=.019)에 따라 유의한 차이가 나타났다. 사후검정(Scheffe's test)결과 체중 증가군($43.50{\pm}4.03$)이 체중변화가 없는 군($29.44{\pm}6.00$)보다 유의하게 수면의 질이 높은 것으로 나타났다. 결론: 폐암환자의 수면의 질과 관련된 변수로 나타난 현재 통증, 주간호제공자, 체중변화의 요인들을 간호제공 시 고려함으로 폐암환자의 수면의 질을 향상시키고, 건강을 증진시킬 수 있으리라 생각된다. 폐암환자의 수면의 질 향상을 위해 수면에 영향을 주는 다른 변인에 관한 연구가 필요하고, 수면을 개선시킬 수 있는 간호 중재방안의 개발이 요구된다.

• Asian Pacific Journal of Cancer Prevention
• /
• 제16권9호
• /
• pp.3673-3676
• /
• 2015

To observe and analyze the characteristic trend of cancer patients hospitalized for the first time in Shanxi Tumor Hospital from 2001 to 2010, clinical data including case number, age, gender, and frequency of different tumor occurrences were collected and statistically analyzed. Results: (i) From 2001 to 2010, the number of cancer patients hospitalized for the first time increased by 1.3-fold; (ii) The patient overall average age also increased from 51.8 to 54.4, for males from 55.5 to 58.7 and females from 48.4 to 51.1, respectively. (iii) Male patients accounted for 43-48% and females accounted for 52-57% of the total. The percentage of female patients was higher than that of male patients in every year and showed an upward trend over the years, while that of the males showed a downward trend (${\chi}^2=7.031$, p=0.008); (iv) Among the top 6 most common cancers, lung, cervical, esophageal, colorectal and breast cancers tended to increase over the years (p<0.05), but not gastric cancer (p=0.423). Conclusions: (i) The number of cancer patients hospitalized for the first time during the past 10 years increased year by year, and was higher for female than male; (ii) the average age of patients increased year after year and was greater for male than female; (iii) the number of patients with lung cancer, cervical cancer, esophageal cancer, colorectal cancer and breast cancer increased over years.

• 한국임상약학회지
• /
• 제12권1호
• /
• pp.1-6
• /
• 2002

Central Cancer Registry of Korean National Cancer Center in 1999 reported that mortality from lung cancer is higher than mortality from stomach cancer or hepatocellular carcinoma in Korean male. Lung cancer is classified into small cell cancer and non-small cell lung cancer (NSCLC), and NSCLC patients account for $70\%$ of the whole lung cancer patients. The purpose of this study was to evaluate the efficacy and toxicity of docetaxel and cisplatin combination in Korean patients with NSCLC. All patients who had received the combination therapy of docetaxel and cisplatin for histologically confirmed NSCLC in Ajou University Hospital between 2000. $2\~2001$. 4 were retrospectively evaluated for the responses and toxicities of that combination therapy. Nineteen patients were treated with docetaxel 75 $mg/m^2$ on Day 1 and cisplatin 25 $mg/m^2$ on Day 1-3 every 4 weeks. The response for combination regimen was evaluated by CT scans after 2 or 3 cycles of treatments. Seventeen patients were evaluated for the responses and the 19 patients far the toxicities. Among the 19 patients (14 men and 5 women), there were one patient $(5.3\%)$ with stage I disease, 4 patients $(21.1\%)$ with stage III disease, and 14 patients $(73.1\%)$ with stage IV disease. Of the 17 patients who were evaluable for response, complete response (CR) was not observed in any patient while partial response (PR) was observed in 5 patients $(29.4\%)$. The overall response rate (CR+PR) was $29.4\%$. Stable disease (SD) was observed in 11 patients $(64.7\%)$ and progressive disease (PD) in 1 patient $(5.9\%)$. The toxicities were graded by NCI (National Cancer Institute) Common Toxicity Criteria for the evaluable 70 cycles. Grade 3 or 4 neutropenia occurred in 53 cycles $(76\%)$. Four patients were hospitalized due to febrile neutropenia. The combination chemotherapy of docetaxel and cisplatin was effective as NSCLC treatments, however, the regimen must be administered carefully due to its hematological side effects.

• Asian Pacific Journal of Cancer Prevention
• /
• 제13권9호
• /
• pp.4373-4378
• /
• 2012

Introduction: Hypercalcemia is mainly caused by bone resorption due to either secretion of cytokines including parathyroid hormone-related protein (PTHrP) or bone metastases. However, hypercalcemia may occur in patients with or without bone metastases. The present study aimed to describe the effect of chemotherapy treatment, regimens and doses on calcium levels among breast and lung cancer patients with hypercalcemia. Methods: We carried a review of medical records of breast and lung cancer patients hospitalized in years 2003 and 2009 at Penang General Hospital, a public tertiary care center in Penang Island, north of Malaysia. Patients with hypercalcemia (defined as a calcium level above 10.5 mg/dl) at the time of cancer diagnosis or during cancer treatment had their medical history abstracted, including presence of metastasis, chemotherapy types and doses, calcium levels throughout cancer treatment, and other co-morbidity. The mean calcium levels at first hospitalization before chemotherapy were compared with calcium levels at the end of or at the latest chemotherapy treatment. Statistical analysis was conducted using the Chi-square test for categorical data, logistic regression test for categorical variables, and Spearman correlation test, linear regression and the paired sample t tests for continuous data. Results: Of a total 1,023 of breast cancer and 814 lung cancer patients identified, 292 had hypercalcemia at first hospitalization or during cancer treatment (174 breast and 118 lung cancer patients). About a quarter of these patients had advanced stage cancers: 26.4% had mild hypercalcemia (10.5-11.9 mg/dl), 55.5% had moderate (12-12.9 mg/dl), and 18.2% severe hypercalcemia (13-13.9; 14-16 mg/dl). Chemotherapy lowered calcium levels significantly both in breast and lung cancer patients with hypercalcemia; in particular with chemotherapy type 5-flurouracil+epirubicin+cyclophosphamide (FEC) for breast cancer, and gemcitabine+cisplatin in lung cancer. Conclusion: Chemotherapy decreases calcium levels in breast and lung cancer cases with hypercalcemia at cancer diagnosis, probably by reducing PTHrP levels.

• Journal of Hospice and Palliative Care
• /
• 제26권1호
• /
• pp.7-17
• /
• 2023

Purpose: The purpose of this study was to analyze end-of-life care practices in lung disease patients with physician orders for life-sustaining treatment (POLSTs). Methods: We retrospectively analyzed data from medical records regarding the end-of-life care practices of POLST decisions for patients with lung disease hospitalized at a tertiary hospital in Seoul, South Korea. Data were collected from January 1 to June 30, 2021. Results: Of 300 total patients, 198 had lung cancer (66.0%) and 102 had non-malignant lung diseases (34.0%). A POLST was written for 187 patients (62.3%), and an advance directive was written for 20 patients (6.7%). Subsequent treatments were hemodialysis in 13 patients (4.3%), surgery in 3 patients (1.0%), and cardiopulmonary cerebral resuscitation in 1 patient (0.3%). Among cancer patients, chemotherapy was performed in 11 patients (3.7%), targeted therapy in 11 patients (3.7%), immunotherapy in 6 patients (2.0%), and radiation therapy in 13 patients (4.3%). Depending on the type of lung disease, types of treatment differed, including hemodialysis, ventilators, bilevel positive airway pressure, high-flow nasal cannulas, nebulizers, enteral nutrition, central line, inotropic agents, and opioids. Conclusion: Although the goals of hospice care are the same whether a patient has lung cancer or a non-malignant lung disease, because the characteristics of the respective diseases differ, end-of-life care practices and hospice approaches must be considered differently.

• Korean Journal of Radiology
• /
• 제25권5호
• /
• pp.481-492
• /
• 2024

Objective: To evaluate the clinical and imaging characteristics of SARS-CoV-2 breakthrough infection in hospitalized immunocompromised patients in comparison with immunocompetent patients. Materials and Methods: This retrospective study analyzed consecutive adult patients hospitalized for COVID-19 who received at least one dose of the SARS-CoV-2 vaccine at two academic medical centers between June 2021 and December 2022. Immunocompromised patients (with active solid organ cancer, active hematologic cancer, active immune-mediated inflammatory disease, status post solid organ transplantation, or acquired immune deficiency syndrome) were compared with immunocompetent patients. Multivariable logistic regression analysis was performed to evaluate the effect of immune status on severe clinical outcomes (in-hospital death, mechanical ventilation, or intensive care unit admission), severe radiologic pneumonia (≥ 25% of lung involvement), and typical CT pneumonia. Results: Of 2218 patients (mean age, 69.5 ± 16.1 years), 274 (12.4%), and 1944 (87.6%) were immunocompromised an immunocompetent, respectively. Patients with active solid organ cancer and patients status post solid organ transplantation had significantly higher risks for severe clinical outcomes (adjusted odds ratio = 1.58 [95% confidence interval {CI}, 1.01-2.47], P = 0.042; and 3.12 [95% CI, 1.47-6.60], P = 0.003, respectively). Patient status post solid organ transplantation and patients with active hematologic cancer were associated with increased risks for severe pneumonia based on chest radiographs (2.96 [95% CI, 1.54-5.67], P = 0.001; and 2.87 [95% CI, 1.50-5.49], P = 0.001, respectively) and for typical CT pneumonia (9.03 [95% CI, 2.49-32.66], P < 0.001; and 4.18 [95% CI, 1.70-10.25], P = 0.002, respectively). Conclusion: Immunocompromised patients with COVID-19 breakthrough infection showed an increased risk of severe clinical outcome, severe pneumonia based on chest radiographs, and typical CT pneumonia. In particular, patients status post solid organ transplantation was specifically found to be associated with a higher risk of all three outcomes than hospitalized immunocompetent patients.

• Korean Journal of Radiology
• /
• 제21권6호
• /
• pp.736-745
• /
• 2020

Objective: To identify the initial chest computed tomography (CT) findings and clinical characteristics associated with the course of coronavirus disease 2019 (COVID-19) pneumonia. Materials and Methods: Baseline CT scans and clinical and laboratory data of 72 patients admitted with COVID-19 pneumonia (39 men, 46.2 ± 15.9 years) were retrospectively analyzed. Baseline CT findings including lobar distribution, presence of ground glass opacities, consolidation, linear opacities, and lung severity score were evaluated. The outcome event was recovery with hospital discharge. The time from symptom onset to discharge or the end of follow-up (for those remained hospitalized) was recorded. Data were censored in events such as death or discharge without recovery. Multivariable Cox proportional hazard regression was used to explore the association between initial CT, clinical or laboratory findings, and discharge with recovery, whereby hazard ratio (HR) values < 1 indicated a lower rate of discharge at four weeks and longer time until discharge. Results: Thirty-two patients recovered and were discharged during the study period with a median length of admission of 16 days (range, 9 to 25 days), while the rest remained hospitalized at the end of this study (median, 17.5 days; range, 4 to 27 days). None died during the study period. After controlling for age, onset time, lesion characteristics, number of lung lobes affected, and bilateral involvement, the lung severity score on baseline CT (> 4 vs. ≤ 4 [reference]: adjusted HR = 0.41 [95% confidence interval, CI = 0.18-0.92], p = 0.031) and initial lymphocyte count (reduced vs. normal or elevated [reference]: adjusted HR = 0.14 [95% CI = 0.03-0.60], p = 0.008) were two significant independent factors that influenced recovery and discharge. Conclusion: Lung severity score > 4 and reduced lymphocyte count at initial evaluation were independently associated with a significantly lower rate of recovery and discharge and extended hospitalization in patients admitted for COVID-19 pneumonia.

• Journal of Preventive Medicine and Public Health
• /
• 제32권2호
• /
• pp.123-129
• /
• 1999

1997년 3월부터 1998년 6월까지 충북대학교병원 내과에 입원하여 치료를 받은 폐암환자 98명과 암 아닌 다른 질환을 가진 대조군 98명을 대상으로 흡연, 음주, 여러 가지 질병과거력 등을 포함한 생활습관과, GSTM1과 GSTT1, 그리고 CYP1A1, CYP1E1 유전자 다형성 양상을 조사하여 다음과 같은 결론을 얻었다. 1. GSTM1의 결손은 환자군이 67.01%, 대조군이 58.16%로 확인되었으며, OR(95% CI)이 1.46(0.82-2.62)으로 폐암 발생에 대해 유의한 영향을 미치지 않는 것으로 나타났다. 2. GSTT1의 결손은 환자군이 58.76%, 대조군이 50.00%로 확인되었으며, OR (95% CD가 1.43(0.81-2.51)으로 폐암 발생과 관련이 없는 것으로 나타났다. 3. CYP1A1 유전자 다형성은 Ile/Ile, Ile/Val, Val/Val 환자군이 각각 59.18%, 35.71%, 5.10%, 대조군이 각각 52.04%, 45.92%, 2.04%로 CYP1A1 유전자 다형성과 폐암 위험도 사이의 관련성은 유의하지 않은 것으로 나타났다$(x^2trend=0.253,\;p-value>0.05)$. 4. CYP1E1 유전자 다형성은 c1/c1, c1/c2, c2/c2 형 이 환자군에서 각각 50.00%, 42.86%, 7.14%, 대조군에서 각각 66.33%, 30.61%, 3.06%로 CYP1E1 활성이 폐암 발생에 유의한 영향을 미치는 것으로 나타났다$(x^2trend=5.783,\;p-value<0.05)$. 특히 환자군이 대조군에 비하여 아주 드문 대립유전자인 c2형이 더 많은 것으로 나타났다. 5. 폐암과 밀접한 연관이 있는 흡연습관의 OR(95% CI)이 3.03(1.58-5.81)으로 확인되어, 폐암의 위험인자로 재확인 되었다. 6. GSTM1, GSTT1, CYP1A1, CYP2-E1과 흡연습관을 포함한 다변량 분석에서 흡연습관만이 유의한 폐암의 위험인자로 나타났다. 이 결과로부터 위의 4가지 유전자의 다형성이 폐암발생에 미치는 영향은, 흡연을 포함한 환경적 요인에 비하여 크지 않을 것으로 판단된다.

• Parasites, Hosts and Diseases
• /
• 제24권1호
• /
• pp.71-76
• /
• 1986

1985년 10월부터 12월 사이에 본병원에 입원한 2명의 환자로부터 Echinostoma sp. 충란을 검출하였다. 이 환자들에게 praziquantel 10mg/kg을 투여하고 하제를 사용한 후 명명 7마리(제 1 예) 및 2마리(제 2 예)의 E. cinetorchis 충체를 수집 동정하였으며 그 결과를 요약하면 다음과 같다. 1. 제1례의 환자는 충북 청주지역에 거주하는 54세 남자로서 심한 체중감소와 빈혈의 증상으로 병원에 입원하였으며, 제2례는 강원도 정선에 거주하는 71세 남자로서 폐암의 증상으로 병원에 입원하였다. 2. 대편검사에서 검출된 충란의 크기는 제1례가 $98{\times}63{\mu}m$(평균), 제2례는 $100{\times}67{\mu\textrm{m}}$(평균)이었다. 환자들에게 구충제와 하제를 투여하고 수집한 충체는 총9마리였다. 충체의 크기는 체장 19.9mm(평균), 체폭 2.77mm(평균)였고 두관 주위의 두극(좌우 end group spine포함(은 37개가 관찰되었다. 고환은 크기와 수 그리고 위치에서 변이를 나타내었다. 3. 제1례가 생식한 논우렁이(Cipangopaludina sp.)에 대한 본흡충 감염 여부를 규명하기 위하여 청주시내의 한 어류상점에서 논우렁이 50마리를 구입하여 조사하였으나 피낭유충을 검출하지 못하였다.

• Journal of Hospice and Palliative Care
• /
• 제17권4호
• /
• pp.241-247
• /
• 2014

목적: 혈청 비타민 C 수치는 체내 항산화상태를 나타내는 지표로서, 암환자에서는 정상인에 비해 감소되어 있다. 하지만, 이 지표가 말기암환자에서 어느 정도 감소되어 있고, 그 감소에 어떤 요인들이 관련되는지에 대한 연구는 매우 드물다. 방법: 두 개 기관의 완화의료병동에 입원했던 암환자 65명을 대상으로 하였다. 환자의 나이, 성별, 암의 종류, 기능상태, 임상증상, 완치 목적의 암 치료력, 그리고 혈청 비타민 C를 포함한 혈액검사 자료를 수집하였다. 혈청 비타민 C 수치의 사분위수를 기준으로 두 군(3사분위수 이하 vs. 4 사분위수)으로 분류한 후 각 군의 차이를 비교하였고, 단계적 다중 로지스틱 회귀분석을 통해 혈청 비타민 C 수치와 관련된 인자를 확인하였다. 결과: 대상자의 혈청 비타민 C의 평균은 $0.44{\mu}g/mL$이었으며, 대상자 전체가 비타민 C 결핍에 해당되었다. 단변량 분석에서는, 비폐암 환자이거나(P=0.041) 발열이 있는 환자(P=0.034)에서 낮은 혈청 비타민 C 수치를 보였다. 폐암, 발열, 삼킴곤란, 호흡곤란, C 반응단백, 그리고 항암화학요법 등의 잠재적인 인자들을 보정한 다변량 분석에서, 낮은 혈청 비타민 C 수치를 나타낼 가능성은 항암화학요법을 받은 군에서 그렇지 않은 군에 비해 3.7배 높았고(P=0.046), 발열이 있는 군에서 그렇지 않은 군에 비해 7.22배 높았다(P=0.020). 결론: 말기암환자에서 비타민 C 부족은 매우 심각하였고, 항암화학요법 치료력과 발열이 관련 있었다.